Preclinical activity of the antibody‐drug conjugate denintuzumab mafodotin (SGN‐CD19A) against pediatric acute lymphoblastic leukemia xenografts-Reference-Cited by-同舟云学术

Preclinical activity of the antibody‐drug conjugate denintuzumab mafodotin (SGN‐CD19A) against pediatric acute lymphoblastic leukemia xenografts

Published:2019-04-23 Issue:8 Volume:66 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Jones Luke¹,McCalmont Hannah¹,Evans Kathryn¹,Mayoh Chelsea¹,Kurmasheva Raushan T.²^ORCID,Billups Catherine A.³,Houghton Peter J.²,Smith Malcolm A.⁴,Lock Richard B.¹

Affiliation:

1. Children's Cancer InstituteSchool of Women's and Children's HealthUNSW Sydney Sydney New South Wales Australia

2. Greehey Children's Cancer Research InstituteUniversity of Texas Health Science Center San Antonio San Antonio Texas

3. St. Jude Children's Research Hospital Memphis Tennessee

4. Cancer Therapy Evaluation ProgramNCI Bethesda Maryland

Funder

National Cancer Institute

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.27765

Reference47 articles.

1. Acute Lymphoblastic Leukemia in Children

2. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

3. Declining childhood and adolescent cancer mortality

4. Genetic Basis of Acute Lymphoblastic Leukemia

5. How I treat relapsed childhood acute lymphoblastic leukemia

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blinatumomab vs Chemotherapy for Pediatric and Adult Acute Lymphoblastic Leukemia;OBM Genetics;2024-07-19

2. Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment;Clinical and Experimental Medicine;2024-03-16

3. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects;Signal Transduction and Targeted Therapy;2023-08-18

4. Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia;Science Translational Medicine;2023-05-17

5. In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts;Pediatric Blood & Cancer;2023-05-04